Please ensure Javascript is enabled for purposes of website accessibility

Why Achillion Pharmaceuticals Stock Is Jumping Today

By Keith Speights - Apr 3, 2019 at 12:50PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Reaching a key clinical study milestone provided a nice boost to the biotech stock.

What happened

Shares of Achillion Pharmaceuticals (ACHN) were jumping 8.8% higher as of 11:49 a.m. EDT on Wednesday after rising as much as 10.8% earlier in the day. The biopharmaceutical company announced before the market opened that it had achieved the threshold enrollment for two phase 2 clinical studies evaluating experimental drug ACH-4471 in treating patients with rare kidney disease C3 glomerulopathy (C3G).

So what

Reaching the threshold enrollment of 23 patients in the two phase 2 clinical studies of ACH-4771 is an important milestone for Achillion. With the needed number of patients now enrolled in the studies, the company is now in a great position to complete the six-month blinded, placebo-controlled trial in the fourth quarter. Achillion's other phase 2 study is a 12-month open-label trial where both patients and investigators are aware of which drug is being administered.

Two scientists looking at a monitor

Image source: Getty Images.

C3G currently has no approved therapy. Patients with the disease experience chronic deposits of C3 protein fragments in their kidneys. This results in inflammation and can lead to permanent kidney damage. Between 30% and 50% of patients with C3G require dialysis and/or a kidney transplant within 10 years of being diagnosed with the rare disease.

ACH-4771 is Achillion's lead pipeline candidate. The company is also evaluating the experimental drug in combination with Alexion Pharmaceuticals' Soliris in treating rare blood disease paroxysmal nocturnal hemoglobinuria (PNH) in a phase 2 study. In December, Achillion stock plunged after the company announced that it wouldn't move forward with a late-stage study of ACH-4771 as a monotherapy in treating PNH.

Now what

Achillion CEO Joe Truitt said that the company expects to present data from the two phase 2 studies of ACH-4771 in treating C3G along with real-world data to the U.S. Food and Drug Administration (FDA) in the fourth quarter of this year. If the results are positive, Achillion should be able to advance the drug to a pivotal phase 3 study in 2020.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Achillion Pharmaceuticals, Inc. Stock Quote
Achillion Pharmaceuticals, Inc.

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/17/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.